50 – Overview of the cGCP Regulatory Landscape (S21E1)

Ever get that feeling. Like you're trying to
understand something big, something important
in healthcare. Like the science behind a new
treatment. Exactly. Or maybe just how those healthcare
decisions even get made. And you realize so much
boils down to these things called clinical trials.
And it hits you. We're trying to make sense of
it all, but it feels like a puzzle. A puzzle
with way too many pieces. And they're all weirdly
shaped. Well today, we're going to simplify that
puzzle. Think of us as your guides. We're going
to walk you through the world of how clinical
trials are actually regulated. And you know what's
great? You send over some really helpful material.
A transcript about CGCP? That's current good
clinical practice. Perfect. In this deep dive,
we're going to unpack all of this regulatory
stuff. We'll break down the key things you absolutely
need to know. Yeah, to understand how they make
sure these clinical trials are safe. And high
quality. Absolutely. No law degree needed. Just
the essential insights. So where do we even start
with all of this? Big picture first. Who are
the main players? We'll talk about the FDA, the
Food and Drug Administration here in the U .S.
They're definitely a central authority. For sure.
We'll also touch on the European Medicines Agency.
The EMA. Right. And of course, the World Health
Organization. The WHO. The global player. Absolutely.
Then we'll look at these super important international
guidelines. Specifically. the ICH guidelines.
I've heard of those. Especially ICH E6 R2. You
got it. That one's crucial. Finally, we'll step
back and look at the history. How did all these
regulations come to be? How they've changed over
time. Exactly. And how they all fit together
to create a worldwide system. A system focused
on making clinical trials ethical. Keeping participants
safe. And making sure they get good, solid data.
Okay, that makes sense. But why even have all
these regulations in the first place? I mean,
what's the core reason for such strict oversight
of clinical trials? That's the big question,
isn't it? To really get it, we've got to take
a quick trip back in time, back to the early
1900s. OK, back in time we go. Back then, the
rules around drugs, they were pretty minimal.
Really? Oh, yeah. The 1906 Pure Food and Drug
Act, that was like the first step. What did that
one do? It stopped companies from selling stuff
that was mislabeled. OK, that makes sense. Or
if the product itself was impure. Makes sense.
But even with the 1912 Shirley Amendment. What
was that all about? Well, that was supposed to
make it easier to prove a company was making
false claims about what a drug could do. Oh,
so like lying about what the drug did? Yeah,
but proving it was still super hard. Oh, wow.
So back then, it was kind of a buyer beware situation.
Pretty much. Companies could make all sorts of
promises. And get away with it. Pretty much,
until this really awful thing happened. Uh -oh.
What happened? The 1937 sulfanilamide tragedy.
It was terrible. What happened? There was this
company, right? And they wanted to make a liquid
form of sulfanilamide. Sulfanilamide? What is
that? It was an antibiotic. So to make it liquid,
they dissolved it in diethylene glycol. Diethylene
glycol. That doesn't sound familiar. Well, it's
highly toxic, like super dangerous. It's used
in antifreeze. Seriously? Yeah. And this product,
the liquid sulfanolamide, it ended up killing
over a hundred people. Oh my gosh. That's just
heartbreaking. And so many of them were children.
It was just awful. I can see why something like
that would immediately make people say, we need
much stricter rules. Absolutely. That event was
a huge turning point. It made everyone realize
it wasn't enough to just stop false claims. Yeah.
You had to prove the drug was safe before it
could even be sold. Exactly. That's a huge shift.
And that's what we still see today, right? Right.
That tragedy led directly to the 1938 Food, Drug,
and Cosmetic Act. That's a big one. Oh, yeah.
For the very first time, a law said, new drugs,
you got to prove they're safe to the FDA. Before
they can go on the market. Before they can go
on the market. It was a big deal. Really the
foundation for how we regulate drugs today. So
that act was like the bedrock. What happened
after that? Well, Things kept developing. In
1944, the Public Health Service Act came along.
What did that one focus on? That one was all
about biological products, things like vaccines.
OK. And blood products, too. Right. Then in 1951,
we got the Durham -Humphrey amendments. What
did those do? Those defined which drugs needed
a prescription. Because they weren't safe to
just use on your own, you know. You needed a
doctor's guidance. Right. So you see this gradual
tightening of the rules, different aspects of
drug safety, how they're used, all being addressed
over time. Step by step. Learning and adapting.
Exactly. Then, in the late 1950s, early 1960s,
another really big thing happened. Oh, no. Not
another tragedy. I'm afraid so. The thalidomide
tragedy. What happened with that one? This drug,
thalidomide, it was being used a lot in Europe
to help pregnant women with morning sickness.
That sounds helpful. Except it caused severe
birth defects. In thousands of babies, it was
devastating. Oh, that's terrible. But here's
the thing. Thalidomide caused all this harm in
many countries, but it was never approved for
widespread use in the United States. Really?
How did that happen? It was largely thanks to
an FDA medical officer, Dr. Frances Kelsey. What
did she do? She insisted on more safety data
before it could be approved. She was really cautious
and thank goodness she was. Wow, that's an incredible
story. So she potentially saved a lot of lives.
Absolutely. Her actions really highlighted how
crucial it is to have that rigorous review process
before a drug can be approved. Right. And to
have these regulatory agencies taking a really
cautious approach. Exactly. So these historical
events, they kind of set the stage for the regulatory
landscape we have today. They do. So let's talk
about those key players on the global scene.
We mentioned the FDA. Yes. The Food and Drug
Administration. Super important here in the U
.S. Huge. What all does the FDA oversee? Their
scope is really broad. It's not just pharmaceuticals.
Really? What else? They also regulate biological
products, medical devices, food, even cosmetics.
Wow. So they have their hands full? They do.
And when it comes to clinical trials for drugs
and biologics, the FDA, they set the standards
for how these studies should be designed, conducted,
and how the results are reported. OK. That makes
sense. And within the FDA's oversight, we often
hear about GCP. Good clinical practice. Can you
remind us what that is exactly? Sure. Good clinical
practice. GCP. It's like a set of rules. Or really
standards. International standards for ethical
and scientific quality. They cover everything.
Designing the trials, conducting them, recording
data, and reporting the results. Wow. Very comprehensive.
It is. And your source material, the clinical
investigator. training course transcript, it
really emphasized how crucial GCP is. Passo.
Well, it ensures that the data from these clinical
trials is reliable. And just as important, it
protects the people participating in the studies.
OK. Their safety, their rights, their well -being.
Exactly. So it's good science and ethical treatment
all rolled into one. You got it. And while the
FDA is a big player in the US, you mentioned
this is a global effort. It is. We also have
the EMA. The European Medicines Agency, they
do similar work in the European Union. And then
there's the WHO. the World Health Organization,
they set international standards and guidelines
for health issues, including clinical research.
So a lot of international collaboration. Definitely.
We may not have all the details on the EMA and
WHO right now, but you always hear them mentioned
when talking about these regulations. It shows
how important they are. Exactly. They're all
part of this big interconnected global system.
So there's a real push for consistency across
the world. There is. And that brings us to those
ICH guidelines. Yes. Can you remind us again
what the ICH is and why their guidelines are
so important? Sure. ICH stands for the International
Council for Harmonization. OK. They're a really
unique group. They bring together regulatory
authorities and pharmaceutical industry experts.
From all over the world. From the US, Europe,
and Japan, primarily. OK. Their goal is to come
up with harmonized guidelines for pharmaceutical
products. Basically, to make the rules more similar
across different regions. Exactly. The idea is
to streamline drug development and the process
for registering new drugs to make it more efficient.
OK, but without cutting corners on safety or
quality, right? Exactly. It's about finding that
balance. So instead of companies having to navigate
all these totally different rules in different
countries, the ICH is trying to create a more
unified approach. That's the goal. And one of
the most important sets of guidelines they've
developed is focused on good clinical practice.
That brings us back to ICH E6 R2. There you go.
This guideline is a cornerstone. It provides
a unified standard for how clinical trials should
be conducted ethically and scientifically. So
no matter where in the world the trial is happening.
Exactly. The main goals of ICH E6 R2 are to make
sure trials are ethical, that the people participating
are safe and their rights are protected. That's
crucial. And that the data from the trial is
high quality. trustworthy. So if a trial follows
ICH E6 R2, it means it meets a globally recognized
standard for quality and ethical conduct. Exactly.
That's good to know. ICH E6 R2 is definitely
a key standard to keep in mind. It is. And keep
in mind, ICH E6 R2 is just one piece of a much
larger puzzle. Right. There are so many other
guidelines. Right. The ICH has developed guidelines
covering a whole bunch of aspects related to
pharmaceuticals, how they're developed, manufactured,
everything. Just to give us an idea, can you
give us a quick overview of some of those other
key ICH guidelines? Sure. We have ICH Q7. It's
all about good manufacturing practice for active
pharmaceutical ingredients. OK, so for the actual
drug substance itself. Right. Then there's ICH
Q8 R2, which focuses on pharmaceutical development.
This one really stresses quality by design. What
does that mean, quality by design? It means you
build quality into the product and the manufacturing
process right from the start. It's not an afterthought.
OK, that makes sense. Then there's ICH Q9. That
one's all about quality risk management. It provides
a system for identifying, assessing, and controlling
any potential problems with quality. Throughout
the whole process, right? Right, from beginning
to end. Then we have ICH Q11. That one's all
about picking the right starting materials. The
stuff used to make the drug substance. OK. So
making sure those ingredients are top notch.
Exactly. And ICH Q4b, that one focuses on making
sure different countries have consistent standards
for drugs. Oh, interesting. We also have ICH
M7, which sets limits for mutagenic impurities.
Mutagenic, meaning they could cause mutations
in DNA. That's right. And then there's ICHQ3A,
which is all about impurities in new drug substances.
So setting thresholds for when impurities need
to be controlled. Exactly. Wow. So there are
a lot of guidelines. It really shows you how
much goes into ensuring these medicines are safe
and effective. It does. It's a complex system,
but it's all connected. And you mentioned earlier
that these regulations are constantly evolving.
They are. Can you tell us more about that? How
have they changed over time? Well, as we talked
about earlier with those historical events, these
regulations aren't set in They've been updated
and revised a lot over the years. In response
to what? New scientific discoveries, for one
thing. New technologies, too. Makes sense. And
sadly, sometimes it takes a tragic event to highlight
a gap in the system. And then they have to make
changes. Exactly. It's important to remember
that different parts of the regulatory system,
they all work together. It's not just a bunch
of separate rules. They support each other. Can
you give us an example of how different regulations
might connect? Sure. Think about GMP, good manufacturing
practices. Usually we think of GMP in terms of
making the final drug product, and there are
specific regulations for that. Like 21 CFR Part
211 for pharmaceuticals. Exactly. And even 21
CFR Part 111 for dietary supplements. But the
basic principles of GMP, ensuring quality, preventing
contamination, keeping good records. Those are
also truthful for clinical trials. Because the
way the drug is made and handled, that affects
the results of the trial. Exactly. So even though
we have different sets of regulations for manufacturing
and clinical trials, they both rely on those
same core principles of quality. That makes sense.
You can't have a good clinical trial if the drug
itself is not high quality. Absolutely. And nowadays,
clinical trials are relying more and more on
computers. Right. Everything is going digital.
So that's where regulations like 21 CFR Part
11 come in. What's that one about? That's the
one about electronic records and electronic signatures.
OK. It sets requirements for making sure that
the digital data in clinical research is trustworthy.
Makes sense. It covers things like validating
the systems, making sure there are audit trails
so you can track any changes to the data. So
it's kind of like those qualification processes
for lab equipment that they talked about in that
YouTube video on GMP Labs for dietary supplements.
Exactly. Those same principles apply to the electronic
systems used in trials. So with everything going
digital... That's added a whole other layer of
regulation. It has. And the FDA wants to make
sure everyone is actually following all these
regulations. Of course. So they have this program
called the Bioresearch Monitoring Program. What
do they do in that program? They inspect clinical
trial sites. Like they go on site? They do. And
they audit the data. To make sure everything
is being done according to GCP. And all the other
relevant regulations, yes. Wow. So they're actively
checking up on the researchers. They are. And
there's this... office within the FDA, the Office
of Scientific Investigations, OSI. They play
a big role in these inspections. That came up
in the FDA training course transcript. So it's
serious business. It is. And there's a growing
trend towards using risk -based approaches in
clinical trials. Risk -based approaches? What's
that? It means you're proactive. you identify
potential risks early on, and you build quality
into the study design from the very beginning,
rather than just waiting for problems to happen
and reacting. So more preventative. Exactly.
Like that idea of quality by design we talked
about earlier. And is there much international
collaboration when it comes to regulation? Absolutely.
Regulatory agencies around the world are sharing
information and working together more and more.
I can see why that would be helpful. It is. It
helps to avoid duplicating work. And it helps
to make sure the regulations are consistent across
different countries. Makes sense. The FDA training
course actually talked about some of these collaborations.
So it really is a global effort, all these agencies
working together. It is. Now, let's shift gears
a bit. Let's talk about the ethical aspects.
Okay. How do these GCP principles and regulations
actually ensure that the people volunteering
for these trials are treated ethically? That's
a really important question. Ethical considerations
are at the very heart of GCP. Right. It's not
just about following rules. It's about doing
the right thing. Exactly. And the regulations
take these ethical principles and translate them
into practical requirements, things researchers
have to actually do. One great example is informed
consent right making sure people understand what
they're getting into Exactly. The regulations
are very clear. You have to give potential participants
all the information about the study. What's the
purpose? What will happen during the trial? What
are the risks? What are the benefits? What are
their rights as participants? All of that has
to be explained before they decide whether or
not to join. It's about giving them the power
to make an informed decision. It is. And there's
a specific form the FDA uses for this, the FDA
1572 form. The critical investigator has to sign
this form, and it includes commitments about
informed consent. So they're legally bound to
uphold those standards. Right. And then there's
the IRB. the Institutional Review Board. What
do they do? They're an independent ethics committee.
Their job is to review and approve the study
protocol and all the other documents, too. Like
the informed consent forms? Exactly. They make
sure the study is ethically sound and that the
risks to the participants are minimized. And
they have to be reasonable. Reasonable compared
to what? Compared to the potential benefits of
the study and the knowledge that might be gained.
So the IRB is like a watchdog looking out for
the participants' well -being. They are. And
they don't just review the study at the beginning.
They keep an eye on it throughout the whole process.
To make sure things stay ethical. Exactly. What
about vulnerable populations, like children or
pregnant women? The regulations have specific
protections for them. There are extra safeguards
to make sure they're not being exploited. That's
really important. It is. And at the end of the
day, the person in charge of the study, the clinical
investigator, they have the ultimate responsibility.
The what? For the safety and well -being of the
participants. And for the integrity of the data.
So if anything goes wrong, it's on them. It is.
The FDA training course was very clear about
that. Even if the investigator delegates tasks
to other people on the study team, they're still
the one who's ultimately accountable. That's
a lot of responsibility. It is. And then there
are rules about reporting adverse events. Adverse
events. any unexpected medical problems that
happen during the trial, those have to be reported
immediately to the appropriate authorities. So
that any potential safety issues can be addressed
quickly. Right. And of course, any other unanticipated
problems also have to be reported. So there's
a lot of emphasis on transparency. Definitely.
And the whole system is designed to make sure
the safety of the participants comes first. That's
good to know. Now, let's talk about the data,
all the information they gather during these
trials. OK. How do the regulations make sure
that data is high quality and trustworthy? That's
a really important part of it because that data,
it's what they use to decide if a new treatment
is safe and effective. Right. It all comes down
to the data. It does. And the regulations have
a bunch of requirements that are all about making
sure that data is accurate and reliable. Can
you walk us through some of those key requirements?
Sure. One of the most fundamental principles
is contemporaneous documentation. Okay. Break
that down for me. What does that mean? It means
all the data. It has to be recorded accurately.
It has to be legible. You have to be able to
read it. It has to be the original record of
the observation. It has to be attributable, meaning
you know who recorded it. And it has to be contemporaneous.
Contemporaneous. Meaning it has to be recorded
at the time the observation was made. So no going
back and filling things in later. Right. You
often hear these principles referred to as LCOA.
LCOA. What's that stand for? Accurate, legible,
contemporaneous, original, and attributable.
OK. Got it. What else? Keeping good records and
storing them properly. That's also crucial. There
are regulations that specify exactly how long
you have to keep those records. How long is it?
Usually, it's at least two years after the drug
gets approved for marketing, or if the application
is withdrawn, though it can vary a bit depending
on what kind of product it is. Right. So everything
is documented and saved for a long time. Yeah.
Just in case. Exactly. It's all about having
that clear audit trail. What else? Another big
thing is sticking to the study plan, the protocol.
Right. You can't just change things up in the
middle of the trial. Exactly. The researchers
have to follow the protocol exactly. And if they
have to deviate from it, they have to document
it and explain why. Makes sense. And the people
working on the trial. They have to be qualified.
Right. They need the right training and expertise.
Absolutely. And we talked about validated systems
earlier. For electronic data capture. Right.
That's really important. It means making sure
those systems are working properly, that they're
reliable. Like that YouTube video on using analytical
instruments in a GMP environment. Exactly. The
same principles apply here. You need accurate
and reliable tools to collect the data. So it's
about more than just the numbers themselves.
It is. It's about the processes, the people,
everything that goes into making sure those numbers
are actually meaningful. Okay. What else is there?
There are rules about calibrating and maintaining
the equipment, making sure it's all working properly,
and there have to be clear procedures for dealing
with any problems that come up. So if something
goes wrong, they have a plan. Exactly. And they
have to investigate thoroughly to figure out
what happened. And the FDA training course mentions
something else that's really important. What's
that? People aren't allowed to share their logging
credentials for the electronic data systems.
Oh, that makes sense. You have to know who entered
what data. Exactly. It's about accountability.
So all these requirements, they all work together
to make sure that the data is trustworthy. They
do. It's a very thorough system. It is. And it's
constantly being refined and improved as science
advances and new technologies come along. It
sounds like it's a never -ending process. It
is. But it's a really important one. This has
been incredibly informative. Can you sum up the
key takeaways you'd want listeners to remember?
Sure. The world of clinical trial regulation,
it's definitely complex. That's for sure. But
it's essential. This framework, it's been built
over many years, learning from mistakes, always
with the goal of protecting people and making
sure the research is ethical. Agencies like the
SDA, the EMA, the WHO, they all play a huge role.
And the ICH guidelines, they're a big part of
making sure things are consistent globally. Right,
a unified approach. Exactly. It's not just about
following the rules, it's about maintaining public
trust in medical research. And ultimately, it's
about protecting patients. That's what it all
comes down to. I think that's a really good way
to put it. It helps put everything into perspective.
I hope so. So knowing all of this, what questions
do you think our listeners should be asking about
clinical trials, about the regulatory process,
anything like that? Well, after this deep dive,
I'd hope they'd be curious to learn more, maybe
delve deeper into some specific aspect of the
regulations. There are so many resources out
there. Like where? Well, all those regulations
we talked about, those are publicly available.
Title 21 of the Code of Federal Regulations,
that's a great place to start. It's all online,
right? It is. So if anyone's really curious,
they can go check it out, see what's really involved
in bringing a new treatment to market. That's
a great tip. Thanks for walking us through all
of this. My pleasure. I think our listeners are
going to find this incredibly helpful. I hope
so. It's a fascinating topic, even if it can
be a bit overwhelming at times. Definitely. But
I think we broke it down pretty well today. I
think so, too. Alright, well until next time,
thanks for joining us. Thanks for having me.